Sara Teresinha Olalla Saad

List of Publications by Year
in descending order

319 papers	4,700 citations	145106 33 h-index	206121 51 g-index
321 all docs	321 docs citations	321 times ranked	7726 citing authors

#	Article	IF	Citations
1	Expression of transforming growth factor Î² pathway components in chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Transplant Immunology, 2022, 70, 101514.	0.6	0
2	Protective effect of green tea and epigallocatechin-3-gallate in a LPS-induced systemic inflammation model. Journal of Nutritional Biochemistry, 2022, 101, 108920.	1.9	13
3	Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer Immunology, Immunotherapy, 2022, 71, 1909-1921.	2.0	5
4	Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition. PLoS ONE, 2022, 17, e0263424.	1.1	3
5	TGF-Î²1 Reduces Neutrophil Adhesion and Prevents Acute Vaso-Occlusive Processes in Sickle Cell Disease Mice. Cells, 2022, 11, 1200.	1.8	5
6	Rac GTPases in acute myeloid leukemia cells: Expression profile and biological effects of pharmacological inhibition. Toxicology and Applied Pharmacology, 2022, 442, 115990.	1.3	8
7	Accelerated lowâ€density neutrophil transition in sickle cell anaemia may contribute to disease pathophysiology. British Journal of Haematology, 2022, 197, 232-235.	1.2	5
8	Effectiveness of a home-based therapeutic exercise program on lower back pain and functionality in Sickle Cell Disease (SCD) patients. Hematology, Transfusion and Cell Therapy, 2021, 43, 268-279.	0.1	1
9	Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematology, Transfusion and Cell Therapy, 2021, 43, 341-348.	0.1	14
10	Effects of home-based inspiratory muscle training on sickle cell disease (SCD) patients. Hematology, Transfusion and Cell Therapy, 2021, 43, 443-452.	0.1	1
11	Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. Small GTPases, 2021, 12, 20-26.	0.7	4
12	Artemisinin-type drugs for the treatment of hematological malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 1-22.	1.1	37
13	Immunomodulatory Effect of Green Tea Treatment in Combination with Low-dose Chemotherapy in Elderly Acute Myeloid Leukemia Patients with Myelodysplasia-related Changes. Integrative Cancer Therapies, 2021, 20, 153473542110026.	0.8	8
14	Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?. Advances in Hematology, 2021, 2021, 1-7.	0.6	11
15	Artesunate Switches Monocytes to an Inflammatory Phenotype with the Ability to Kill Leukemic Cells. International Journal of Molecular Sciences, 2021, 22, 608.	1.8	10
16	3D Scaffolds to Model the Hematopoietic Stem Cell Niche: Applications and Perspectives. Materials, 2021, 14, 569.	1.3	23
17	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 2021, 39, 736-746.	1.2	7
18	Hematopoietic Cell Kinase (HCK) Is a Player of the Crosstalk Between Hematopoietic Cells and Bone Marrow Niche Through CXCL12/CXCR4 Axis. Frontiers in Cell and Developmental Biology, 2021, 9, 634044.	1.8	7

#	Article	IF	Citations
19	(â€“)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1. Scientific Reports, 2021, 11, 9103.	1.6	22
20	Ex Vivo Manufacture of Megakaryocytes and Platelets from Stem Cells: Recent Advances Toward Transfusion in Humans. Stem Cells and Development, 2021, 30, 351-362.	1.1	0
21	Evaluation of different protocols for culturing mesenchymal stem cells derived from murine bone marrow. Hematology, Transfusion and Cell Therapy, 2021, , .	0.1	1
22	New germline GATA1 variant in females with anemia and thrombocytopenia. Blood Cells, Molecules, and Diseases, 2021, 88, 102545.	0.6	3
23	Deficiency of ARHGAP21 alters megakaryocytic cell lineage responses and enhances platelet hemostatic function. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119012.	1.9	4
24	Polyphenolic Flavonoid Compound Quercetin Effects in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Molecules, 2021, 26, 5781.	1.7	8
25	Platelet counts on peripheral blood and Mean Platelet Volume as markers of clinical severity in Sickle Cell Disease. Blood Cells, Molecules, and Diseases, 2021, 91, 102592.	0.6	0
26	Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 168, 76-89.	2.0	24
27	Artemisinins induce endoplasmic reticulum stress in acute leukaemia cells in vitro and in vivo. EJHaem, 2021, 2, 818.	0.4	0
28	Artesunate strongly modulates myeloid and regulatory T cells to prevent LPS-induced systemic inflammation. Biomedicine and Pharmacotherapy, 2021, 143, 112211.	2.5	5
29	Crizanlizumab Therapy Is Associated with Lower Levels of Circulating Extracellular Vesicles in Sickle Cell Disease Patients. Blood, 2021, 138, 955-955.	0.6	0
30	Arhgap21 Deficiency Results in Increase of Osteoblastic Lineage Cells in the Murine Bone Marrow Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 718560.	1.8	2
31	Final Results of the Fibromet Trial: An Open Label Phase II Study to Evaluate Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients. Blood, 2021, 138, 2584-2584.	0.6	1
32	A Novel WNT5A-Mimicking Peptide Affects Leukemia Cell Survival in the Bone Marrow Microenvironment. Blood, 2021, 138, 2949-2949.	0.6	0
33	Myelodysplastic Syndromes: Have You Seen Your Patient Beyond His Hemoglobin?. Blood, 2021, 138, 4660-4660.	0.6	0
34	CXCR4hi effector neutrophils in sickle cell anemia: potential role for elevated circulating serotonin (5-HT) in CXCR4hi neutrophil polarization. Scientific Reports, 2020, 10, 14262.	1.6	3
35	Novel Non-Coding Transcript in NR4A3 Locus, LncNR4A3, Regulates RNA Processing Machinery Proteins and NR4A3 Expression. Frontiers in Oncology, 2020, 10, 569668.	1.3	1
36	ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells. Blood Cells, Molecules, and Diseases, 2020, 84, 102460.	0.6	4

#	Article	IF	Citations
37	Prevalence of Bartonella spp. Infection in Patients with Sickle Cell Disease. Vector-Borne and Zoonotic Diseases, 2020, 20, 509-512.	0.6	3
38	Platelet Counts and Mean Platelet Volume As Markers of Clinical Severity in Sickle Cell Disease. Blood, 2020, 136, 36-37.	0.6	0
39	Reduction of ARHGAP21 Alters Platelet Biogenesis in Vitro and Accelerates Hemostatic Response In Vivo. Blood, 2020, 136, 13-13.	0.6	0
40	ARHGAP21 deficiency impairs hepatic lipid metabolism and improves insulin signaling in lean and obese mice. Canadian Journal of Physiology and Pharmacology, 2019, 97, 1018-1027.	0.7	7
41	The challenges of handling deferasirox in sickle cell disease patients older than 40 years. Hematology, 2019, 24, 596-600.	0.7	8
42	Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients. Annals of Hematology, 2019, 98, 2507-2521.	0.8	29
43	Recombinant erythropoietin as alternative to red cell transfusion in sickle cell disease. Vox Sanguinis, 2019, 114, 178-181.	0.7	6
44	Characterization of a novel decellularized bone marrow scaffold as an inductive environment for hematopoietic stem cells. Biomaterials Science, 2019, 7, 1516-1528.	2.6	23
45	Echocardiografic abnormalities in patients with sickle cell/Î²-thalassemia do not depend on the Î²-thalassemia phenotype. Hematology, Transfusion and Cell Therapy, 2019, 41, 158-163.	0.1	2
46	S100A8 acts as an autocrine priming signal for heme-induced human MÏ• pro-inflammatory responses in hemolytic inflammation. Journal of Leukocyte Biology, 2019, 106, 35-43.	1.5	10
47	Whole-exome sequencing indicates FLG2 variant associated with leg ulcers in Brazilian sickle cell anemia patients. Experimental Biology and Medicine, 2019, 244, 932-939.	1.1	7
48	Hypocholesterolemia and dysregulated production of angiopoietin-like proteins in sickle cell anemia patients. Cytokine, 2019, 120, 88-91.	1.4	4
49	An update on arginine in sickle cell disease. Expert Review of Hematology, 2019, 12, 235-244.	1.0	10
50	LEF1â€AS1, long nonâ€coding RNA, inhibits proliferation in myeloid malignancy. Journal of Cellular and Molecular Medicine, 2019, 23, 3021-3025.	1.6	23
51	BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Frontiers in Oncology, 2019, 9, 16.	1.3	34
52	Exosomes in the serum of Acute Myeloid Leukemia patients induce dendritic cell tolerance: Implications for immunotherapy. Vaccine, 2019, 37, 1377-1383.	1.7	20
53	Technetium-99m-dimercaptosuccinic acid renal scintigraphy and single photon emission computed tomography/computed tomography in patients with sickle cell disease. Nuclear Medicine Communications, 2019, 40, 1158-1165.	0.5	2
54	Small Particles, Big Effects: The Interplay Between Exosomes and Dendritic Cells in Antitumor Immunity and Immunotherapy. Cells, 2019, 8, 1648.	1.8	16

#	Article	IF	Citations
55	Upâ€regulation of <scp>SPINT</scp>2/<scp>HAI</scp>â€2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion. Journal of Cellular and Molecular Medicine, 2019, 23, 1562-1571.	1.6	13
56	Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET). Blood, 2019, 134, 554-554.	0.6	3
57	NRF2 Is Targeted By the Polyphenol Quercetin and Induces Apoptosis, in Part, through up Regulation of Pro Apoptotic Mirs. Blood, 2019, 134, 2529-2529.	0.6	4
58	Epigallocatechin-3-Gallate Induces Cellular Differentiation and Reduces Leukemia Burden in PML/RarÎ± Mice By Increasing Reactive Oxygen Species and Reducing PIN1 Expression. Blood, 2019, 134, 5765-5765.	0.6	0
59	Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care. Blood, 2019, 134, 4681-4681.	0.6	1
60	Mutations in Triple-Negative Patients with Myeloproliferative Neoplasms. Blood, 2019, 134, 5395-5395.	0.6	2
61	Expression of Notch Pathway Components in Primary Samples of Allogeneic Hematopoietic Cell Transplant Patients with Chronic Graft Versus Host Disease. Blood, 2019, 134, 5600-5600.	0.6	0
62	Quiescence/Mobilization of Hematopoietic Immature Cells Induced By Polyphenols through Modulation of APC/EPCR/PAR-1 Axis. Blood, 2019, 134, 4996-4996.	0.6	0
63	A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment. Blood, 2019, 134, 4650-4650.	0.6	0
64	Sickle Cell Disease Patients Have Altered Number and Function of Dendritic Cells. Blood, 2019, 134, 3569-3569.	0.6	0
65	Antitumor activities of Quercetin and Green Tea in xenografts of human leukemia HL60 cells. Scientific Reports, 2018, 8, 3459.	1.6	74
66	Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects. Biomedicine and Pharmacotherapy, 2018, 99, 237-244.	2.5	2
67	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. Hematology, Transfusion and Cell Therapy, 2018, 40, 92-95.	0.1	0
68	The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 959-966.	1.8	8
69	Serine peptidase inhibitor Kunitz type 2 (SPINT2) in cancer development and progression. Biomedicine and Pharmacotherapy, 2018, 101, 278-286.	2.5	31
70	Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells. Leukemia and Lymphoma, 2018, 59, 1501-1504.	0.6	8
71	Novel mutations associated with pyruvate kinase deficiency in Brazil. Hematology, Transfusion and Cell Therapy, 2018, 40, 5-11.	0.1	11
72	Hematopoietic defects in response to reduced Arhgap21. Stem Cell Research, 2018, 26, 17-27.	0.3	18

#	Article	IF	Citations
73	Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model. Cancer Letters, 2018, 414, 116-126.	3.2	19
74	The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes. Clinical Epigenetics, 2018, 10, 139.	1.8	65
75	Differences in heme and hemopexin content in lipoproteins from patients with sickle cell disease. Journal of Clinical Lipidology, 2018, 12, 1532-1538.	0.6	14
76	Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study. Annals of Hematology, 2018, 97, 2039-2046.	0.8	15
77	CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells. Stem Cell Research and Therapy, 2018, 9, 34.	2.4	20
78	Combined Administration of Recombinant TGF-Î²1 and DMSO Decreases the in Vitro Inflammatory Properties of Neutrophils from Sickle Cell Anemia Individuals. Blood, 2018, 132, 2366-2366.	0.6	0
79	Elevated Levels of Hepatokine Angiopoietin-like 3 Correlate Paradoxically with Hypocholesterolemia and Hemolysis in Sickle Cell Anemia. Blood, 2018, 132, 1069-1069.	0.6	0
80	Polyphenols Modulate Quiescence/Mobilization of Hematopoietic Immature Cells through APC/EPCR/PAR-1 Axis. Blood, 2018, 132, 3830-3830.	0.6	0
81	De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Scientific Reports, 2017, 7, 40707.	1.6	29
82	Natural Type II Collagen Hydrogel, Fibrin Sealant, and Adipose-Derived Stem Cells as a Promising Combination for Articular Cartilage Repair. Cartilage, 2017, 8, 439-443.	1.4	15
83	SEMA3A partially reverses VEGF effects through binding to neuropilin-1. Stem Cell Research, 2017, 22, 70-78.	0.3	28
84	Stathmin 1 expression in plasma cell neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 183-185.	0.7	1
85	Telomere length correlates with disease severity and inflammation in sickle cell disease. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 140-145.	0.7	11
86	Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice. Journal of Nutritional Biochemistry, 2017, 50, 16-25.	1.9	193
87	Fatty acid is a potential agent for bone tissue induction: InÂvitro and inÂvivo approach. Experimental Biology and Medicine, 2017, 242, 1765-1771.	1.1	14
88	Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the â^'1774delG polymorphism in the Abcc2 gene. Clinical Case Reports (discontinued), 2017, 5, 1218-1221.	0.2	10
89	Coinheritance of Hb Bristol-Alesha [Î²67(E11)Valâ†'Met;HBB: c.202G>A] and the Î±212 Patchwork Allele in a Brazilian Child with Severe Congenital Hemolytic Anemia. Hemoglobin, 2017, 41, 203-208.	0.4	6
90	Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 450-461.	1.8	25

#	Article	IF	Citations
91	Echocardiografic Abnormalities in Patients with Sickle Cell/Î²-Thalassemia Do Not Depend on the Î²-Thalassemia Phenotype. Blood, 2017, 130, 987-987.	0.6	0
92	Reduced rate of sickleâ€related complications in Brazilian patients carrying HbFâ€promoting alleles at the BCL11A and HMIPâ€2 loci. British Journal of Haematology, 2016, 173, 456-460.	1.2	25
93	Transfusion service management of sickleâ€cell disease patients. Vox Sanguinis, 2016, 110, 288-294.	0.7	6
94	LDH and age are associated with hemolysis-endothelial dysfunction in HbSC patients. Blood Cells, Molecules, and Diseases, 2016, 59, 119-123.	0.6	0
95	Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 147-157.	0.7	3
96	Cytokine polymorphisms in sickle cell disease and the relationship withÂcytokine expression. Experimental Hematology, 2016, 44, 583-589.	0.2	14
97	Amputations in Sickle Cell Disease: Case Series and Literature Review. Hemoglobin, 2016, 40, 150-155.	0.4	4
98	Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 368-370.	0.7	2
99	The effects of exchange transfusion for prevention of complications during pregnancy of sickle hemoglobin C disease patients. Transfusion, 2016, 56, 119-124.	0.8	18
100	BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine. Haematologica, 2016, 101, e445-e448.	1.7	15
101	Sickle cell/Î²-thalassemia: Comparison of SÎ²⁰ and SÎ²⁺ Brazilian patients followed at a single institution. Hematology, 2016, 21, 623-629.	0.7	12
102	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagnostic Pathology, 2016, 11, 28.	0.9	16
103	Interactions of sickle red blood cells with neutrophils are stabilized on endothelial cell layers. Blood Cells, Molecules, and Diseases, 2016, 56, 38-40.	0.6	2
104	Inflammasome-Dependent IL-1Î² Release from Neutrophils in Human Sickle Cell Anemia. Blood, 2016, 128, 854-854.	0.6	3
105	CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells. Oncotarget, 2016, 7, 68385-68396.	0.8	20
106	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, 2016, 7, 6948-6959.	0.8	20
107	Modulation of Hemolytic and Hemoglobin/Heme Scavenging Profiles in Sickle Cell Anemia, Hereditary Spherocytosis and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2016, 128, 1257-1257.	0.6	0
108	Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells. Blood, 2016, 128, 1886-1886.	0.6	0

#	Article	IF	Citations
109	ROS Production Triggers Anti-Leukemic Effects of Green Tea. Blood, 2016, 128, 5219-5219.	0.6	0
110	ANKHD1 Silencing Delays S Phase Progression in Multiple Myeloma Cells Via Activation of ATM/ATR -CDC25a Pathway. Blood, 2016, 128, 5624-5624.	0.6	0
111	Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea. Haematologica, 2015, 100, 730-739.	1.7	34
112	Role of innate immunity-triggered pathways in the pathogenesis of Sickle Cell Disease: a meta-analysis of gene expression studies. Scientific Reports, 2015, 5, 17822.	1.6	48
113	Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome. Haematologica, 2015, 100, e491-e493.	1.7	11
114	Overexpression and Characterization of the C-Terminal Domain of Human SIVA1: A Proapoptotic Factor and Cytoskeleton Binding Protein. Protein and Peptide Letters, 2015, 23, 43-50.	0.4	3
115	InÂvitro microfluidic model for the study of vaso-occlusive processes. Experimental Hematology, 2015, 43, 223-228.	0.2	21
116	Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica, 2015, 100, 466-471.	1.7	29
117	Motivating medical students to learn basic science concepts using chronic myeloid leukemia as an integration theme. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 63-66.	0.7	2
118	Tenâ€Elevenâ€Translocation 2 (<scp>TET</scp>2) is downregulated in myelodysplastic syndromes. European Journal of Haematology, 2015, 94, 413-418.	1.1	18
119	Differential profile of PIP4K2A expression in hematological malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 228-235.	0.6	6
120	Useful properties of undifferentiated mesenchymal stromal cells andÂadipose tissue as the source in liver-regenerative therapy studied inÂanÂanimal model of severe acute fulminant hepatitis. Cytotherapy, 2015, 17, 1052-1065.	0.3	30
121	Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. European Journal of Cancer, 2015, 51, 2076-2085.	1.3	21
122	Pilot randomized controlled trial to evaluate the effect of aquatic and land physical therapy on musculoskeletal dysfunction of sickle cell disease patients. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 82-89.	0.7	12
123	Imatinib restores VASP activity and its interaction with Zyxin in BCRâ€“ABL leukemic cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 388-395.	1.9	14
124	Umbilical cord blood <scp>CD</scp>34⁺ stem cells and other mononuclear cell subtypes processed up to 96Âh from collection and stored at room temperature maintain a satisfactory functionality for cell therapy. Vox Sanguinis, 2015, 108, 72-81.	0.7	8
125	Leukocyte Telomere Length Correlates with Disease Severity and Inflammation in Sickle Cell Disease. Blood, 2015, 126, 2173-2173.	0.6	2
126	Natural Scaffold, from Bovine Bone Marrow, Reproduces Native Microenvironment and Supports CD34+ and Stromal Cells. Blood, 2015, 126, 2400-2400.	0.6	1

#	Article	IF	Citations
127	A Novel Antisense Long Noncoding RNA Modulates NR4A1 Protein Level in Myeloid Malignancies. Blood, 2015, 126, 2442-2442.	0.6	1
128	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. Oncotarget, 2015, 6, 29573-29584.	0.8	16
129	Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome. Blood Transfusion, 2015, 13, 53-8.	0.3	22
130	Antisense Long Non-Coding RNA in the LEF1 Locus Regulates Sense LEF1 Expression in Leukemic Cell Line KG1. Blood, 2015, 126, 3586-3586.	0.6	0
131	Knockdown of HCK Reduces Cell Death and Erythroid Differentiation in Human CD34+ Hematopoietic Progenitor Cells. Blood, 2015, 126, 2860-2860.	0.6	0
132	ANKHD1 Is Essential for Repair of DNA Double-Strand Breaks in Multiple Myeloma. Blood, 2015, 126, 1762-1762.	0.6	7
133	Pharmacological IRS1/2 Inhibition Reduces Cell Viability in BCR-ABL1 Positive Cells. Blood, 2015, 126, 2772-2772.	0.6	0
134	ARHGAP21 Is Upregulated and Triggers the Modulation of Rho Gtpase Signaling Pathways during Megakaryocytic Differentiation. Blood, 2015, 126, 4760-4760.	0.6	0
135	Methylation of HAI-2/SPINT2 in Bone Marrow Mesenchymal Stromal Cells of MDS and AML Patients Affects Hematopoietic Stem Cell Survival and Adhesion. Blood, 2015, 126, 2847-2847.	0.6	0
136	CXCR7 Participates in Chemotaxis and Homing Mediated By CXCL12. Blood, 2015, 126, 3601-3601.	0.6	0
137	CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12. PLoS ONE, 2014, 9, e85926.	1.1	49
138	Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 442-444.	0.7	1
139	Serine Protease Inhibitor Kunitz-Type 2 Is Downregulated in Myelodysplastic Syndromes and Modulates Cellâ€“Cell Adhesion. Stem Cells and Development, 2014, 23, 1109-1120.	1.1	8
140	Autologous Platelet Gel. International Journal of Lower Extremity Wounds, 2014, 13, 120-126.	0.6	10
141	YAP1expression in myelodysplastic syndromes and acute leukemias. Leukemia and Lymphoma, 2014, 55, 2413-2415.	0.6	11
142	Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: AssociaÃ§Ã£o MÃ©dica Brasileira â€“ 2014. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 450-453.	0.7	0
143	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia, 2014, 28, 78-87.	3.3	256
144	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leukemia Research, 2014, 38, 251-257.	0.4	28

#	Article	IF	Citations
145	Mesenchymal stromal cells from adipose tissue attached to suture material enhance the closure of enterocutaneous fistulas in a rat model. Cytotherapy, 2014, 16, 1709-1719.	0.3	13
146	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, 2014, 38, 1245-1251.	0.4	47
147	Pyrimidine-5â€²-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5â€²-nucleotidase type I deficiency and influence of Gilbert's Syndrome on clinical expression. Blood Cells, Molecules, and Diseases, 2014, 53, 246-252.	0.6	3
148	Obesity and inflammation and the effect on the hematopoietic system. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 147-151.	0.7	12
149	Multitarget Effects of Quercetin in Leukemia. Cancer Prevention Research, 2014, 7, 1240-1250.	0.7	57
150	PIPKIIÎ± is widely expressed in hematopoietic-derived cells and may play a role in the expression of alpha- and gamma-globins in K562 cells. Molecular and Cellular Biochemistry, 2014, 393, 145-153.	1.4	3
151	ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Experimental Cell Research, 2014, 324, 137-145.	1.2	46
152	The Cratylia mollis Seed Lectin Induces Membrane Permeability Transition in Isolated Rat Liver Mitochondria and a Cyclosporine Aâ€‰insensitive Permeability Transition in Trypanosoma cruzi Mitochondria. Journal of Eukaryotic Microbiology, 2014, 61, 381-388.	0.8	13
153	Coagulation Activation By Heme: Evidence from Global Hemostasis Assays. Blood, 2014, 124, 455-455.	0.6	2
154	Cytokines Polymorphisms and Relationship with Cytokine Expression in Sickle Cell Disease. Blood, 2014, 124, 4910-4910.	0.6	1
155	Endothelial Activation by Platelets from Sickle Cell Anemia Patients. PLoS ONE, 2014, 9, e89012.	1.1	35
156	Stathmin 1 in normal and malignant hematopoiesis. BMB Reports, 2014, 47, 660-665.	1.1	36
157	Arhgap21 Expression in Bone Marrow Niche Is Crucial for Hematopoietic Progenitor Homing and Short Term Reconstitution after Transplantation. Blood, 2014, 124, 1591-1591.	0.6	0
158	Hematopoietic Cell Kinase (HCK) Is Involved in Myelodysplastic Syndromes and Acute Leukemia Pathophysiology By Modulating PI3K Pathway and Enhancing Erythroid Differentiation. Blood, 2014, 124, 1891-1891.	0.6	1
159	BRD4 Short Isoform Is a Myelodysplasia Prognostic Marker Involved in Inappropriate DNA Damage Response. Blood, 2014, 124, 3234-3234.	0.6	0
160	ANKHD1 Is Required for S Phase Progression and Histone Gene Transcription in Multiple Myeloma. Blood, 2014, 124, 2002-2002.	0.6	0
161	Repeat Course of Rabbit Antithymocyte Globulin As Salvage Following Initial Therapy with Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. Blood, 2014, 124, 2944-2944.	0.6	1
162	Cellular and Molecular Effects of NVP-BKM120 in Lymphoblastic Leukemia Cells. Blood, 2014, 124, 2241-2241.	0.6	0

#	Article	IF	Citations
163	IRS2 Inhibition Reduces Cell Proliferation and Has Cumulative Effects with Ruxolitinib in JAK2 V617F Cells. Blood, 2014, 124, 3219-3219.	0.6	0
164	Stathmin 1 Silencing Amplifies Ruxolitinib-Induced Apoptosis in JAK2V617F Cells. Blood, 2014, 124, 3229-3229.	0.6	0
165	Randomized Clinical Trial to Evaluate the Effect of Two Physical Therapy Programs in Musculoskeletal Dysfunction in Subjects with Sickle Cell Disease. Blood, 2014, 124, 5982-5982.	0.6	0
166	Differentially Expressed Genes and Pathways in Endothelial Cells Exposed to Hemin or Plasma from Patients with Sickle Cell Disease: A Meta-Analysis of Gene Expression Studies. Blood, 2014, 124, 4018-4018.	0.6	0
167	Gene Expression Analysis of the Brazilian Type of Hereditary Persistence of Fetal Hemoglobin: Identification of Genes that Could be Related to Î³-Globin Activation. Hemoglobin, 2013, 37, 516-535.	0.4	4
168	FMNL1 promotes proliferation and migration of leukemia cells. Journal of Leukocyte Biology, 2013, 94, 503-512.	1.5	41
169	IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. Leukemia Research, 2013, 37, 541-546.	0.4	23
170	Increased adhesive and inflammatory properties in blood outgrowth endothelial cells from sickle cell anemia patients. Microvascular Research, 2013, 90, 173-179.	1.1	27
171	Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. Clinical Biochemistry, 2013, 46, 1798-1803.	0.8	19
172	MDR-1 and GST polymorphisms are involved in myelodysplasia progression. Leukemia Research, 2013, 37, 970-973.	0.4	8
173	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 365-374.	1.8	50
174	Low expression of tissue inhibitor of metalloproteinase-2 may be associated with high-risk myelodysplastic syndrome. Leukemia and Lymphoma, 2013, 54, 1091-1093.	0.6	1
175	ARHGAP21 Protein, a New Partner of Î±-Tubulin Involved in Cell-Cell Adhesion Formation and Essential for Epithelial-Mesenchymal Transition. Journal of Biological Chemistry, 2013, 288, 2179-2189.	1.6	49
176	Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores. PLoS ONE, 2013, 8, e81048.	1.1	22
177	Hedgehog Pathway Is Deregulated In Myelodysplastic Syndrome Progenitor Bone Marrow Cells. Blood, 2013, 122, 1533-1533.	0.6	4
178	HPFH and Delta-Beta Thalassemia Have Different Profiles Of Micrornas and Transcription Factors. Blood, 2013, 122, 186-186.	0.6	4
179	Familial Mastocytosis: Identification Of KIT K509I Mutation and Its In Vitro Sensitivity To Imatinib, Dasatinib and PKC412. Blood, 2013, 122, 5267-5267.	0.6	2
180	PTK2 and PTPN11 expression in myelodysplastic syndromes. Clinics, 2013, 68, 1371-1375.	0.6	0

#	Article	IF	Citations
181	Imaging Flow Cytometry and Microfluidic Flow Assays Demonstrate Heterocellular Aggregation Of Immature Sickle Erythrocytes To Neutrophils Via Mac-1/VLA-4 Interactions. Blood, 2013, 122, 318-318.	0.6	1
182	Quercetin Induces Autophagy, Apoptosis and Cell Cycle Arrest In P39 Cells. Blood, 2013, 122, 5042-5042.	0.6	0
183	IRS2 Associates With JAK2 and May Be Involved In Cell Proliferation Pathways In Chronic Myeloproliferative Neoplasms. Blood, 2013, 122, 1598-1598.	0.6	0
184	Inhibition Of the Rho/Rho-Kinase Pathway Reduces In Vitro Adhesion Of Sickle Cell Anemia Eosinophils To Human Endothelial Cells. Blood, 2013, 122, 2219-2219.	0.6	1
185	Green Tea In Acute Myeloid Leukemia. Blood, 2013, 122, 5032-5032.	0.6	0
186	Inflammasome and Autophagy Activation In Symptomatic Multiple Myeloma Could Predict Response To Thalidomide-Based Chemotherapy. Blood, 2013, 122, 3131-3131.	0.6	0
187	Antimyeloma In Vitro Activity Of 15-Deoxy-D12,14-Prostaglandin J2 Is Associated With Endoplasmic Reticulum Stress In a Reactive Oxygen Species-Dependent Fashion. Blood, 2013, 122, 4913-4913.	0.6	0
188	VASP Protein, a Binding Partner Of BCR-ABL and FAK, May Be Implicated In The Chronic Myeloid Leukemia Phenotype. Blood, 2013, 122, 5162-5162.	0.6	0
189	Increased Platelet-Derived CD40L May Modulate Endothelial Cell ICAM-1 Expression and Interact With Leukocytes In Sickle Cell Anemia. Blood, 2013, 122, 974-974.	0.6	0
190	Ndfip Is a Novel Autophagy Regulator and It Is Deregulated In Acute Myeloid Leukemia. Blood, 2013, 122, 1419-1419.	0.6	10
191	ANKHD1 Silencing Reduces In Vitro Clonogenicity and In Vivo Tumorogenicity Of Multiple Myeloma Cells. Blood, 2013, 122, 3168-3168.	0.6	0
192	Stathmin 1 Is Involved In The Highly Proliferative Phenotype Of High-Risk Myelodysplastic Syndromes and Acute Leukemia Cells. Blood, 2013, 122, 861-861.	0.6	0
193	FMNL1 Is Downregulated In Myelodysplastic Syndromes and Is Involved In Megakaryocytic Differentiation. Blood, 2013, 122, 1519-1519.	0.6	0
194	Elevated plasma levels and plateletâ€associated expression of the proâ€thrombotic and proâ€inflammatory protein, <scp>T</scp>NFSF14 (LIGHT), in sickle cell disease. British Journal of Haematology, 2012, 158, 788-797.	1.2	30
195	Postâ€translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. FEBS Letters, 2012, 586, 3522-3528.	1.3	10
196	ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. FEBS Letters, 2012, 586, 4311-4318.	1.3	30
197	Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients. Leukemia Research, 2012, 36, 1300-1303.	0.4	18
198	Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. Neoplasma, 2012, 59, 530-535.	0.7	4

#	Article	IF	Citations
199	Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes. Leukemia Research, 2012, 36, 554-559.	0.4	11
200	Proangiogenic Effects of Plasma From Sickle Cell Disease Patients and Antiangiogenic Effects of Hydroxyurea: Evaluation of Invasion and Proliferation of Human Endothelial Cells and Effects of Hydroxyurea in a Mouse Matrigel Plug Neovascularization Assay. Blood, 2012, 120, 377-377.	0.6	1
201	Monocyte Shift to a Non-Classical CD14dim/CD16+ Phenotype Correlates with Fetal Hemoglobin Levels in Sickle Cell Anemia Patients Treated with Hydroxyurea. Blood, 2012, 120, 817-817.	0.6	1
202	Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis. PLoS ONE, 2012, 7, e43090.	1.1	97
203	Autophagy Regulation and Dysfunction in Bone Marrow Malignancies. Blood, 2012, 120, 4623-4623.	0.6	0
204	Elevation of Hypercoagulability Markers in Hemoglobin SC Disease. Blood, 2012, 120, 3227-3227.	0.6	0
205	Hematopoietic Cell Kinase (HCK) Is Highly Expressed in Myelodysplastic Syndrome (MDS) and Regulates Proliferation, Cell Cycle Progression and Hematopoietic Differentiation. Blood, 2012, 120, 3813-3813.	0.6	0
206	Hedgehog Ligands and Receptors Are Deregulated in Myelodysplastic Syndromes. Blood, 2012, 120, 3817-3817.	0.6	0
207	BNIP3 Is Downregulated in Myelodysplastic Syndromes and Acute Myeloid Leukemia and Is a Potential Molecular Target for Decitabine. Blood, 2012, 120, 1708-1708.	0.6	0
208	Reduced TET2 expression in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia.. Blood, 2012, 120, 2822-2822.	0.6	0
209	The Cytoskeleton Proteins VASP and Zyxin Participate in Hematopoiesis and in the BCR-ABL Signaling Pathway.. Blood, 2012, 120, 2780-2780.	0.6	0
210	Platelets From Sickle Cell Disease Individuals Induce Endothelial Activation, Demonstrating ICAM-1 and E-Selectin Adhesion Molecule Expression, Inflammatory Cytokine Production and Activation of NFÎºB Transcription Factor Gene Expression.. Blood, 2012, 120, 2114-2114.	0.6	0
211	Correlation Between IL10 and CD8+ Cells in MDS Patients Adds New Insight Into the Role of the Immune System in This Disease. Blood, 2012, 120, 3836-3836.	0.6	0
212	ANKHD1 Interacts with the Proapoptotic Protein SIVA and Plays a Role in the Proliferation and Stathmin Activation of Acute Leukemia Cells.. Blood, 2012, 120, 2419-2419.	0.6	0
213	Low bone mass density is associated with hemolysis in brazilian patients with sickle cell disease. Clinics, 2011, 66, 801-805.	0.6	33
214	Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1404-1411.	1.9	22
215	Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals. Inflammation Research, 2011, 60, 633-642.	1.6	19
216	Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers. Leukemia Research, 2011, 35, 1102-1107.	0.4	9

#	Article	IF	Citations
217	Alterations in cell maturity and serum survival factors may modulate neutrophil numbers in sickle cell disease. Experimental Biology and Medicine, 2011, 236, 1239-1246.	1.1	8
218	Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica, 2011, 96, 526-533.	1.7	33
219	Hydroxyurea Reduces the Hypercoagulable State In Sickle Cell Anemia. Blood, 2011, 118, 1068-1068.	0.6	1
220	Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS. Blood, 2011, 118, 461-461.	0.6	10
221	ANKHD1 Silencing Induces S-Phase Arrest and Modulates Cell Cycle Gene Expression in Human Myeloma Cells. Blood, 2011, 118, 1828-1828.	0.6	0
222	Th17/Treg Imbalance in Sickle Cell Disease and Hydroxyurea Therapy. Blood, 2011, 118, 1050-1050.	0.6	0
223	In Vitro and In Vivo downregulation of Leukemogenesis by FMNL1 Inhibition In Namalwa Cell Line. Blood, 2011, 118, 1485-1485.	0.6	1
224	SDF-1 Signaling in Myeloid Malignancies,. Blood, 2011, 118, 3824-3824.	0.6	7
225	Adhesive and Inflammatory Properties Are Increased in Blood Outgrowth Endothelial Cells From Patients with Sickle Cell Anemia. Blood, 2011, 118, 2133-2133.	0.6	0
226	The CALM/AF10 Interactor CATS Is a Substrate of KIS, a Positive Regulator of Cell Cycle Progression in Leukemia Cells. Blood, 2011, 118, 2549-2549.	0.6	0
227	Downregulation of IRS2 in Myelodysplastic Syndrome (MDS) May Be Related to Impaired Cell Differentiation,. Blood, 2011, 118, 3814-3814.	0.6	0
228	Hepcidin Production in Ineffective Erythropoiesis and Chronic Hemolysis: Insights on the Crosstalk Between Erythropoiesis and Iron Metabolism. Blood, 2011, 118, 346-346.	0.6	1
229	Increased Angiogenic Activity of Plasma From Sickle Cell Disease Patients and Anti-Angiogenic Effects of Hydroxyurea: Evaluation of Capillary-Like Structure Formation of Human Umbilical Vein Endothelial Cells on Matrigel. Blood, 2011, 118, 899-899.	0.6	3
230	Abnormal Expression of Ndfip2 and Cbl in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Role of Ubiquitin Proteasome System in Myeloid Neoplasms and Normal Hematopoiesis. Blood, 2011, 118, 2567-2567.	0.6	1
231	Expressions of KLF1, FOXO3a, HOOK3 and MIER1 genes Are Associated with Fetal Hemoglobin Levels in Hereditary Persistence of Fetal Hemoglobin,. Blood, 2011, 118, 3195-3195.	0.6	13
232	MDR-1 and GST Polymorphisms Are Involved in Myelodysplasia Progression,. Blood, 2011, 118, 3507-3507.	0.6	0
233	FMNL1 Is Involved in Immune Response and Hematopoietic Differentiation in MDS. Blood, 2011, 118, 1735-1735.	0.6	0
234	CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates the Chemotactic Response to SDF-1. Blood, 2011, 118, 1482-1482.	0.6	0

#	Article	IF	Citations
235	Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. Clinics, 2011, 66, 793-9.	0.6	3
236	Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with Type 2 diabetes. Journal of Diabetes and Its Complications, 2010, 24, 192-198.	1.2	43
237	Identification of protein-coding and non-coding RNA expression profiles in CD34+and in stromal cells in refractory anemia with ringed sideroblasts. BMC Medical Genomics, 2010, 3, 30.	0.7	14
238	Regulation of Chondrogenesis by Transforming Growth Factor-ÃŸ3 and Insulin-like Growth Factor-1 from Human Mesenchymal Umbilical Cord Blood Cells. Journal of Rheumatology, 2010, 37, 1519-1526.	1.0	22
239	Increased adhesive properties of platelets in sickle cell disease: roles for Î±_{IIb}Î²₃â€mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. British Journal of Haematology, 2010, 149, 280-288.	1.2	24
240	Fermented papaya preparation for Î²-thalassemia?. Expert Review of Hematology, 2010, 3, 265-268.	1.0	0
241	Platelet-Associated IgG May Be Associated with Thrombocytopenia In Patients with Myelodysplastic Syndromes. Blood, 2010, 116, 2943-2943.	0.6	0
242	Formin-Like 1 (FMNL1) Associates with Rac1 and Negatively Regulates Neoplastic Growth and Migration in Leukemia Cell Lines.. Blood, 2010, 116, 1030-1030.	0.6	0
243	Elevated Plasma Levels and Platelet-Associated Expression of the Pro-Thrombotic and Pro-Inflammatory Protein, LIGHT (TNFSF14), In Sickle Cell Anemia (SCA). Blood, 2010, 116, 2651-2651.	0.6	1
244	IRS2 Is Dowregulated In Primary MDS Cells and During MDS Erythroid Differentiation. Blood, 2010, 116, 1886-1886.	0.6	0
245	Knockdown of Insulin Receptor Substrate 1 (IRS1); a Partner of BCR-ABL, Results In Decrease In Proliferation and Downregulation of AKT/mTOR and MAPK Pathways In K562 Cells. Blood, 2010, 116, 4459-4459.	0.6	0
246	Altered Functional Properties of Eosinophils In Sickle Cell Anemia and Effects of Hydroxyurea Therapy. Blood, 2010, 116, 2656-2656.	0.6	10
247	Hydroxyurea Induces Hepcidin Expression In Monocytes In Sickle Cell Anemia Patients. Blood, 2010, 116, 2653-2653.	0.6	0
248	Impaired red cell deformability in iron deficient subjects. Clinical Hemorheology and Microcirculation, 2009, 43, 217-221.	0.9	30
249	PIP4KIIA and Î²â€globin: transcripts differentially expressed in reticulocytes and associated with high levels of Hb H in two siblings with Hb H disease. European Journal of Haematology, 2009, 83, 490-493.	1.1	9
250	High Levels of Human Î³-Globin are Expressed in Adult Mice Carrying a Transgene of the Brazilian Type of Hereditary Persistence of Fetal Hemoglobin (^AÎ³ â^'195). Hemoglobin, 2009, 33, 439-447.	0.4	3
251	Upâ€regulation of NADPH oxidase components and increased production of interferonâ€gamma by leukocytes from sickle cell disease patients. American Journal of Hematology, 2008, 83, 41-45.	2.0	13
252	High expression of the cGMPâ€specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. British Journal of Haematology, 2008, 142, 836-844.	1.2	30

#	Article	IF	Citations
253	Reduction of AHSP synthesis in hemin-induced K562 cells and EPO-induced CD34+ cells leads to Î±-globin precipitation, impairment of normal hemoglobin production, and increased cell death. Experimental Hematology, 2008, 36, 265-272.	0.2	14
254	The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Molecular Oncology, 2008, 2, 356-367.	2.1	36
255	ARHGAP21 associates with FAK and PKCÎ¶ and is redistributed after cardiac pressure overload. Biochemical and Biophysical Research Communications, 2008, 374, 641-646.	1.0	20
256	Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica, 2008, 93, 605-609.	1.7	70
257	Enalapril therapy and cardiac remodelling in sickle cell disease patients. Acta Cardiologica, 2008, 63, 599-602.	0.3	10
258	Chronic Liver Abnormalities in Sickle Cell Disease: A Clinicopathological Study in 70 Living Patients. Acta Haematologica, 2007, 118, 129-135.	0.7	29
259	Reduced expression of FLIPSHORT in bone marrow of low risk myelodysplastic syndrome. Leukemia Research, 2007, 31, 853-857.	0.4	4
260	Inhibition of caspaseâ€dependent spontaneous apoptosis via a cAMPâ€protein kinase A dependent pathway in neutrophils from sickle cell disease patients. British Journal of Haematology, 2007, 139, 148-158.	1.2	25
261	Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. European Journal of Haematology, 2007, 79, 330-337.	1.1	33
262	Leukocyte numbers correlate with plasma levels of granulocyteâ€“macrophage colony-stimulating factor in sickle cell disease. Annals of Hematology, 2007, 86, 255-261.	0.8	45
263	Phylogenetic Analysis of RhoGAP Domain-Containing Proteins. Genomics, Proteomics and Bioinformatics, 2006, 4, 182-188.	3.0	8
264	ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 828-834.	1.8	33
265	Identification of novel candidate genes for globin regulation in erythroid cells containing large deletions of the human Î²-globin gene cluster. Blood Cells, Molecules, and Diseases, 2006, 37, 82-90.	0.6	21
266	51Cr-EDTA measurements of the glomerular filtration rate in patients with sickle cell anaemia and minor renal damage. Nuclear Medicine Communications, 2006, 27, 959-962.	0.5	19
267	Risk factors for conjunctival and retinal vessel alterations in sickle cell disease. Acta Ophthalmologica, 2006, 84, 234-241.	0.4	15
268	An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nature Genetics, 2006, 38, 807-812.	9.4	172
269	Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leukemia Research, 2006, 30, 9-16.	0.4	29
270	High expression of FMNL1 protein in T non-Hodgkin's lymphomas. Leukemia Research, 2006, 30, 735-738.	0.4	30

#	Article	IF	Citations
271	Causes of incidental neutropenia in adulthood. Annals of Hematology, 2006, 85, 705-709.	0.8	35
272	Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. European Journal of Haematology, 2006, 78, 061205033335001-???.	1.1	42
273	Pancytopenia in Untreated Patients with Graves' Disease. Thyroid, 2006, 16, 403-409.	2.4	54
274	Band 3Tambau: a de novo mutation in the AE1 gene associated with hereditary spherocytosis. Implications for anion exchange and insertion into the red blood cell membrane. European Journal of Haematology, 2005, 74, 396-401.	1.1	9
275	Polymorphisms of interleukin-1 gene complex, IL6 and tumour necrosis factor genes in chronic idiopathic neutropenia of adults. Annals of Hematology, 2005, 84, 709-714.	0.8	10
276	Effect of Cytokines and Chemokines on Sickle Neutrophil Adhesion to Fibronectin. Acta Haematologica, 2005, 113, 130-136.	0.7	41
277	Characterisation of a new splice variant of MASK-BP3ARF and MASK human genes, and their expression patterns during haematopoietic cell differentiation. Gene, 2005, 363, 113-122.	1.0	3
278	DNAase I Hypersensitive Site 3â€² to the Î²-Globin Gene Cluster Containing Two TAA Insertions and a Gâ†'A Polymorphism is Predominantly Associated with the Î²+-Thalassemia IVS-I-6 (Tâ†'C) Mutation. Hemoglobin, 2005, 29, 85-89.	0.4	0
279	DNAase I hypersensitive site 3' to the beta-globin gene cluster containing two TAA insertions and a G-->A polymorphism is predominantly associated with the beta+-thalassemia IVS-I-6 (T-->C) mutation. Hemoglobin, 2005, 29, 85-9.	0.4	1
280	Association of the G-463A myeloperoxidase polymorphism with infection in sickle cell anemia. Haematologica, 2005, 90, 977-9.	1.7	14
281	Lack of Arg972 Polymorphism in the IRS1 Gene in Parakana Brazilian Indians. Human Biology, 2004, 76, 147-151.	0.4	2
282	Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. British Journal of Haematology, 2004, 124, 547-554.	1.2	47
283	Expression of Î±-hemoglobin stabilizing protein gene during human erythropoiesis. Experimental Hematology, 2004, 32, 157-162.	0.2	42
284	Increased adhesive properties of eosinophils in sickle cell disease. Experimental Hematology, 2004, 32, 728-734.	0.2	21
285	Association of glucose-6-phosphate dehydrogenase deficiency and X-linked chronic granulomatous disease in a child with anemia and recurrent infections. American Journal of Hematology, 2004, 75, 151-156.	2.0	18
286	Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. American Journal of Hematology, 2004, 76, 343-347.	2.0	44
287	Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. American Journal of Hematology, 2004, 77, 45-49.	2.0	52
288	Regulation of the GATA3 promoter by human T-cell lymphotropic virus type I Tax protein. Journal of Cellular Biochemistry, 2004, 93, 1178-1187.	1.2	5

#	Article	IF	Citations
289	Detection and Possible Prognostic Relevance ofp53Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature. Leukemia and Lymphoma, 2004, 45, 2071-2078.	0.6	37
290	?-cardiac actin (ACTC) binds to the band 3 (AE1) cardiac isoform. Journal of Cellular Biochemistry, 2003, 89, 1215-1221.	1.2	9
291	Simple fluorescent PCR method for detection of large deletions in the ?-globin gene cluster. American Journal of Hematology, 2003, 72, 225-227.	2.0	8
292	Human leukocyte formin: a novel protein expressed in lymphoid malignancies and associated with Akt. Biochemical and Biophysical Research Communications, 2003, 311, 365-371.	1.0	46
293	BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS Letters, 2003, 535, 17-22.	1.3	27
294	Mild hemolysis in a girl with G6PD SumarÃ© (class I variant) associated with G6PD Aâˆ’. Blood Cells, Molecules, and Diseases, 2003, 30, 238-240.	0.6	5
295	Unsuccessful treatment of sideroblastic anaemia with chloroquine. Revista Brasileira De Hematologia E Hemoterapia, 2003, 25, 67.	0.7	1
296	Apoptosis-Regulating Proteins and Prognosis in Diffuse Large B Cell Non-Hodgkinâ€™s Lymphomas. Acta Haematologica, 2002, 107, 29-34.	0.7	19
297	The Gly972Arg Polymorphism in Insulin Receptor Substrate-1 Is Associated With Decreased Birth Weight in a Population-Based Sample of Brazilian Newborns. Diabetes Care, 2002, 25, 550-553.	4.3	16
298	Mutations in the p53 Gene in Acute Myeloid Leukemia Patients Correlate with Poor Prognosis. Hematology, 2002, 7, 13-19.	0.7	22
299	Liver transplantation in a patient with S??O-thalassemia.. Transplantation, 2002, 74, 896-898.	0.5	20
300	Molecular Heterogeneity of G6PD Deficiency in an Amazonian Population and Description of Four New Variants. Blood Cells, Molecules, and Diseases, 2002, 28, 399-406.	0.6	26
301	Progesterone Upregulates GATA-1 on Erythroid Progenitors Cells in Liquid Culture. Blood Cells, Molecules, and Diseases, 2002, 29, 213-224.	0.6	11
302	ARHGAP10, a novel human gene coding for a potentially cytoskeletal Rho-GTPase activating protein. Biochemical and Biophysical Research Communications, 2002, 294, 579-585.	1.0	53
303	A NOVELÎ²-GLOBIN VARIANT: Hb POÃ‡OS DE CALDAS [Î²61(E5)Lysâ†’Gln]. Hemoglobin, 2002, 26, 385-388.	0.4	1
304	Blood group genotyping facilitates transfusion of ?-thalassemia patients. Journal of Clinical Laboratory Analysis, 2002, 16, 216-220.	0.9	35
305	DNAase I hypersensitive site 3' to the beta-globin gene cluster contains a TAA insertion specific for beta(S)-Benin haplotype. Haematologica, 2002, 87, 246-9.	1.7	2
306	High expression of apoptosis-regulating proteins in Burkitt's lymphomas. Haematologica, 2002, 87, ELT16.	1.7	0

#	Article	IF	Citations
307	Î²-Spectrin StaBÃ¡rbara: a novel frameshift mutation in hereditary spherocytosis associated with detectable levels of mRNA and a germ cell line mosaicism. British Journal of Haematology, 2001, 115, 347-353.	1.2	7
308	p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. American Journal of Hematology, 2001, 67, 84-92.	2.0	43
309	Association of the Î±-spectrin R28H mutation with allele Î±LELY and with Î±I/Î±II domain haplotypes in three Brazilian families. European Journal of Haematology, 2000, 64, 53-58.	1.1	2
310	A recurrent frameshift mutation of the ankyrin gene associated with severe hereditary spherocytosis. British Journal of Haematology, 2000, 111, 1190-1193.	1.2	16
311	Haematopoietic response and bclâ€2 expression in patients with acute myeloid leukaemia. European Journal of Haematology, 1999, 62, 38-42.	1.1	21
312	Arginine 490 is a hot spot for mutation in the band 3 gene in hereditary spherocytosis. European Journal of Haematology, 1999, 63, 360-361.	1.1	7
313	Haplotype analysis andAÎ³ gene polymorphism associated with the Brazilian type of hereditary persistence of fetal hemoglobin. , 1998, 58, 49-54.		3
314	Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahidrofolate reductase among patients with sickle cell disease in Brazil. , 1998, 59, 46-50.		57
315	Relationship Between the Type of BCR-ABL Rearrangement and Bone Marrow Histopathological Features in Chronic Myeloid Leukemia. Acta OncolÃ³gica, 1997, 36, 313-315.	0.8	0
316	Î²â€Spectrin Campinas: a novel shortened Î²â€chain variant associated with skipping of exon 30 and hereditary elliptocytosis. British Journal of Haematology, 1997, 97, 579-585.	1.2	8
317	G6PD SumarÃ©: A novel mutation in the G6PD gene (1292 Tâ†'G) associated with chronic nonspherocytic anemia. , 1997, 10, 245-247.		10
318	The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. British Journal of Haematology, 1996, 93, 333-340.	1.2	69
319	Red cell membrane protein abnormalities in hereditary spherocytosis in Brazil. British Journal of Haematology, 1994, 88, 295-299.	1.2	31